|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Strep pneumoniae IgG Ab, 23 serotypes
Test CodeSTR23
Preferred Specimen
1 mL serum
Minimum Volume
0.4 mL
Transport Container
Plastic vial
Transport Temperature
Refrigerated
Specimen Stability
14 days refrigerated
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia
Report Available
4-7 days
Reference Range
See report for normal ranges
Clinical Significance
Bacterial polysaccharides induce a T-cell independent type II humoral immune. Vaccines containing bacterial polysaccharides can be effective in generating an immune response that results in production of IgG antibodies and generation of long-lived plasma and memory B cells, which can protect an individual against bacterial disease. Active immunization of adults and children >2 years is performed with nonconjugated polysaccharide vaccines (Pneumovax and Pnu-Immune 23) that contain a total of 23 serotypes, namely 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.(3) These 23 serotypes were included because, as a group, they account for approximately 90% of invasive pneumococcal infections. Antibody responses develop in approximately 75% to 85% of nonimmunocompromised adults and older children approximately 4 to 6 weeks following immunization.